the Spanish hypogonadism/spermatogenesis/subcutaneous self-administration/testicular size
Introduction

Spain
Male hypogonadotrophic hypogonadism (HH) has been 2 To whom correspondence should be addressed successfully treated for several decades by administration of The efficacy and safety of highly purified follicle stimulating gonadotrophins (Finkel et al., 1985; Ley and Leonard, 1985 ; hormone (FSH) associated with human chorionic gonado- Okuyama et al., 1986) , which allows the restoration of testicutrophin (HCG) was studied in 60 men with hypogonadolar steroidogenesis and spermatogenesis. Human chorionic trophic hypogonadism. Of these men, 16 suffered from gonadotrophin (HCG) is normally used as the source of Kallmann's syndrome, 19 from idiopathic hypogonadoluteinizing hormone (LH) activity to stimulate testosterone trophic hypogonadism and 25 from hypopituitarism. Basal secretion by Leydig cells, whereas human menopausal gonadotestosterone concentrations were found to be far below the trophin (HMG) has been generally used as the follicle stimulatnormal range. At baseline, 26 patients were able to ejaculate ing hormone (FSH) source to stimulate proliferation and and all of them showed azoospermia, while the remaining maturation of germinal cells. patients were aspermic. All patients self-administered s.c.
Since spermatogenesis is a time-consuming process, any attempt aimed at its restoration must rely on a long-term injections of FSH (150 IU ⍥ three/week) and HCG (2500 treatment; normally, thrice-weekly intramuscular (i.m.) HMG IU ⍥ two/week) for at least 6 months and underwent injections have been administered for several months. The i.m. periodic assessments of testicular function. Testosterone administration involves various inconveniences, such as local concentrations increased rapidly during treatment and all pain or need to visit a health centre for injections, which are but one patient reached normal values. Testicular volume particularly relevant in the case of a chronic treatment, thus showed a sustained increase reaching almost 3-fold its decreasing compliance and often leading to the interruption of baseline value. At the end of treatment, 48 patients (80.0%) treatment before spermatogenesis has been achieved (Saal had achieved a positive sperm count. The maximum sperm et al., 1991) . Thus, the availability of a treatment which could concentration during treatment was 24.5 ⍨ 8.1 ⍥ 10 6 /ml be given s.c. is especially advantageous since it would be less (mean ⍨ SEM). The median time to induce spermatogenpainful and could be done by the patient himself, with a better esis was 5 months. Eleven patients reported adverse events, cost-benefit ratio. On the other hand, the s.c. route has been generally not related to treatment. Three patients experishown to produce more sustained and less fluctuating FSH enced gynaecomastia. No local reactions at injection site concentrations as compared to those obtained by the i.m. route were observed. In conclusion, the s.c. self-administration (Handelsman et al., 1995 Howles et al., 1994) .
Llobregat (Barcelona); J.García-Arnés, Hospital Carlos Haya, 29010
The purpose of this study was to assess the efficacy and At screening, a medical history was obtained and a physical examinaconducted in accordance with the Declaration of Helsinki and in tion was performed. In addition to routine laboratory parameters, compliance with good clinical practice. Each patient gave written baseline hormonal concentrations of prolactin, thyroid stimulating informed consent before entering the study.
hormone (TSH), thyroid hormones, and cortisol were determined. LH and FSH concentrations were measured basally and after GnRH Patient selection stimulation, and plasma testosterone concentrations were estimated also basally and after HCG stimulation, as follows: after a basal The study population consisted of males suffering from HH with plasma sample was collected, 2500 IU HCG were administered s.c. azoospermia or aspermia, aged between 18 and 45 years, with low twice a week for 4 consecutive weeks. Three days after the last HCG plasma testosterone concentrations (Ͻ200 ng/dl) which responded to injection, blood was obtained again, spun and the plasma used to HCG stimulation, and plasma LH/FSH concentrations below or at measure post-stimulation testosterone concentrations. At all timethe lower normal limit; a washout period of at least 2 months points at least two blood samples were collected with a ജ20 min for previous treatment with testosterone/HCG and 6 months for interval and were assayed either separately or as a pool. In the case gonadotrophin releasing hormone (GnRH) or HMG was established.
of independent assay, testosterone concentration was defined as the Exclusion criteria were: relevant systemic diseases or treatments mean of values obtained in each aliquot. Testosterone concentrations which might influence the study results or drug pharmacokinetics;
were measured in plasma obtained from heparin-or EDTA-treated body mass index (BMI) Ͼ28.3; existence of other non-treated pituitary blood. Measurements were performed using a commercially available deficiencies; hyperresponse to the GnRH stimulation test; infection radioimmunoassay method. Testosterone measurements were repeated of genital tract; bilateral anorchia; mechanical abnormalities impairing after 1, 3, 6 or 9 months of treatment. sperm collection; hyperprolactinaemia; varicocele; cryptorchidism; Spermiograms were performed under basal conditions (two intellectual deficiency or inability to comply with the study procedures.
spermiograms at least 7 days apart within 3 months before entering Study drugs the study), and then monthly from the third month of treatment onwards. Seminal fluid was collected by masturbation after 3-5 days FSH-HP (Metrodin HP ® , Serono, Madrid, Spain) was supplied as of abstinence using glass or plastic containers, avoiding the use lyophilized powder in ampoules, each containing 75 or 150 IU FSH of condoms. Sperm samples were immediately transported to the (batch nos 0615/s, 17501042, 17504082, 17521123 and 17502035).
laboratory, avoiding delays of Ͼ1 h or exposure to extremes of HCG (Profasi HP ® , Serono) was supplied as a lyophilized powder in temperature. Spermiograms were assessed according to the World ampoules, each containing 2500 IU HCG (batch nos P-5371, I-5 and Health Organization (WHO, 1992) criteria, using a haemocytometer J-2).
to measure sperm concentration.
Treatment schedule
To assess testicular size, the short and long axis of each testis was measured with a caliper basally and at each subsequent visit. Testicular Before starting combined gonadotrophin treatment, written informed volume was calculated according to the following formula (Ley and consent was obtained from each patient and compliance with Leonard, 1985) : elegibility criteria was verified; this included a positive testosterone response to HCG administration (2500 IU, twice a week) over 4 V ϭ 4/3 π (a/2) 2 b/2 weeks. Then, all eligible patients self-administered s.c. injections of FSH-HP (150 IU, three times a week) and HCG (2500 IU, twice a where a represents the short testicular axis and b the long testicular week). The HCG dose was reduced in three patients due to abnormal axis (in cm). Volumes (V) are expressed in ml, as the average of testosterone responses or gynaecomastia. Combined treatment needed both testicles. to be carried out for at least 6 months; at the end of this period, if
Penis length was measured at the beginning of the study and at no adequate spermatogenic response had been obtained, treatment each subsequent visit using a caliper. Pubic hair was assessed initially was to be extended for at least 3 additional months.
and at each subsequent visit using Tanner's classification. At the end of the treatment period, testicular biopsy samples were taken in some End points of the patients who had not responded. Adverse events and physical examination results were recorded at The primary efficacy end point was the spermatogenic response in each visit. Routine laboratory tests were performed basally and terms of sperm concentration. The response was defined as complete periodically during treatment. if a sperm concentration of at least 1 ϫ 10 6 /ml was achieved during treatment, whereas it was considered as partial in the case of sperm Statistical methods appearance in the ejaculate with a concentration Ͻ1 ϫ 10 6 /ml. Secondary end points for efficacy included total sperm count, sperm
The protocol aimed for the inclusion of at least 60 evaluable patients, since this sample size was considered to be representative of the quality in terms of motility, morphology and viability, ejaculate volume, plasma testosterone concentrations, testicular size and secondstudied population, taking into account the low incidence of HH. To assess treatment efficacy, the proportion of patients achieving a ary sexual characteristics.
Safety was assessed in terms of adverse events, physical examinaspermatogenic response and the corresponding 95% confidence interval (CI) were calculated. Basal values of sperm concentration and tion (including injection site) and routine laboratory tests, including haematological parameters (red blood cell count, haemoglobin, haemtotal sperm count were compared with maximum values obtained after treatment, using Wilcoxon's matched pairs signed-ranks test. atocrit, leukocyte numbers and differential count and platelets), blood chemistry [glucose, creatinine, total proteins, bilirubin, serum Testosterone plasma concentrations at the different time-points were analysed by Friedman's test and the evolution of ejaculate volume, testicular volume and penis size were analysed using analysis of variance (ANOVA) for repeated measures. Concerning pubic hair, baseline status was compared with that reached at the end of treatment, using Wilcoxon's matched pairs signed-ranks test.
To assess the influence of several prognostic factors, the response to treatment was compared in different diagnostic groups, as well as in terms of previous treatments, testicular volume, and pre-or post-pubertal onset of hypogonadism. Correlation between different variables was analysed using the Pearson r coefficient.
To assess treatment safety, further to calculating the incidence of adverse events and physical examination or laboratory findings, the evolution of laboratory parameters from baseline throughout the treatment was assessed by ANOVA for repeated measures.
Statistical significance was defined as a P value Ͻ0.05. 
Study population
Treatment was initiated in 63 patients, but three of them were Testosterone plasma concentrations withdrawn from the study because of ineligibility, severe
At the beginning of the study, all patients had testosterone headache and personal reasons respectively, before any efficacy concentrations far below the normal range (0.4 Ϯ 0.1 ng/ml, assessment could be performed. Thus, 60 patients could be mean Ϯ SEM). As shown in Figure 1 , testosterone plasma assessed for efficacy while 63 patients were considered for the concentrations increased considerably in response to the HCG safety analysis.
test and continued increasing during combined treatment with Treatment compliance was correct in the vast majority of HCG and FSH-HP reaching a value of 8.8 Ϯ 0.9 ng/ml patients, with only three patients being considered as poor (mean Ϯ SEM) after 6 months of treatment (P Ͻ0.001). All compliants.
patients achieved testosterone concentrations within the normal range (Ͼ3 ng/ml), with the exception of one patient with Demographic and other baseline characteristics a minimal testicular volume (0.4 ml), whose testicular biopsy after 9 months of treatment revealed interstitial fibrosis and Demographic, epidemiological and baseline characteristics of the 60 patients included in the efficacy analysis are summarized absence of Leydig's cells in both testes. in Table I . The study sample consisted of relatively young Testicular volume patients, 35 showing isolated HH (Kallmann's syndrome or idiopathic HH) and 25 with hypopituitarism. The disease Figure 2 shows the evolution of testicular volume, which experienced a sustained and significant increase with the started before puberty in 52 patients. Most patients had been previously treated with testosterone, either as a single treatment treatment from 4.3 Ϯ 0.5 ml at baseline to 11.1 Ϯ 1.0 after 6 months (P Ͻ0.001). All but one patient experienced an increase or preceded by gonadotrophin administration, while three patients had never been treated. during treatment and 14 achieved a normal testicular volume for a healthy adult (Ͼ16 ml). The testicular volume at 6 months of treatment was significantly correlated with that shown at baseline (r ϭ 0.5; P Ͻ0.01).
Spermatogenic response
At the beginning of the study, only 26 patients (43.3%) were able to ejaculate and all of them showed azoospermia, while the rest of patients were aspermic. After 6 months of treatment, 28 patients (46.7%) had achieved a sperm concentration Ͼ1 ϫ 10 6 /ml and all of them finished the study at this point except four patients who were willing to continue therapy. The remaining 32 patients who had not achieved an adequate response were asked to extend treatment for at least 3 additional months. Three of these patients refused to continue therapy for personal reasons and another one was withdrawn from the study because of an adverse event, so 28 out of 32 patients with no adequate response continued treatment beyond 6 months. Table II shows the proportion of patients who achieved a spermatogenic response during the study period. At the end of treatment, an adequate response was observed in 39 (65%) patients while another nine patients showed a positive sperm count with a sperm concentration Ͻ1 ϫ 10 6 /ml. Thus, the overall response rate was 48/60 (80.0%) (95% CI: 67.3-88.8%). Testicular specimens were obtained in those non- revealed testicular fibrosis and/or spermatogenesis arrested at early stages.
A survival analysis of time required to induce spermatogenesis is shown in Figure 3 . The median time to achieve a positive motility was observed in 44.1 Ϯ 4.0% (mean Ϯ SEM) of spermatozoa, with a normal morphology in 56.4 Ϯ 8.5% and sperm count was 5 months (95% CI: 3.31-6.69 months).
The evolution of sperm concentration throughout the study viability in 64.3 Ϯ 4.9% of spermatozoa. These values did not show significant changes at subsequent assessments throughout period is shown in Figure 4 . All patients who were able to ejaculate basally (n ϭ 26) showed azoospermia. Sperm the treatment period. concentration increased progressively over the treatment period Ejaculate volume achieving an average maximum value of 24.5 Ϯ 8.1 ϫ 10 6 /ml (mean Ϯ SEM), significantly higher (P Ͻ0.001) than the Prior to the beginning of treatment, the ejaculate volume in those patients who produced sperm samples was 1.2 Ϯ 0.2 ml pre-treatment value. In all, 14 patients reached a sperm concentration within the normal range (Ͼ20 ϫ 10 6 /ml, accord-(mean Ϯ SEM). Ejaculate volume was promptly and significantly (P Ͻ0.001) increased by gonadotrophin treatment so that ing to WHO criteria). Total sperm count showed a similar pattern, increasing from a 0 value at baseline up to a maximum a normal volume was achieved, on average, at 3 months (2.4 Ϯ 0.2 ml, mean Ϯ SEM) and was maintained over the of 59.8 Ϯ19.7 ϫ 10 6 spermatozoa per ejaculate (mean Ϯ SEM) during treatment (P Ͻ0.001).
treatment period. Out of 34 patients who were not able to ejaculate at the Sperm motility, morphology and viability could not be assessed at baseline since all the patients capable of ejaculating beginning, 30 started to do so during treatment and reached normal volumes. presented with azoospermia. After 3 months of treatment,
Secondary sexual characteristics
which could be related to the combined treatment with FSH-HP ϩ HCG. One of them presented with intense headache Penis length increased significantly (P Ͻ0.001) over the leading him to withdraw from the study. Three patients showed treatment period from 6.0 Ϯ 0.3 cm (mean Ϯ SEM) at baseline mild or moderate bilateral gynaecomastia, which improved in to 8.1 Ϯ 0.3 cm at 6 months. Regarding pubic hair, prior to one case after HCG dose reduction. One patient suffered from starting treatment 20% of patients were prepubertal (Tanner's acne, probably related to HCG administration. Only two serious stage I-II). However, after 5 months of treatment all patients adverse events were observed during treatment, both occurring had reached Tanner's stage III-V (P Ͻ0.01).
in the same patient; the first event was a surgical intervention due to coxa vara, not related to the study drugs; then, after 6 Pregnancies months of treatment, the patient presented with an episode of Most patients included in the study were not interested in benign intracranial hypertension, considered as possibly related immediate procreation. Only four patients manifested their to treatment, which caused the patient's withdrawal from the desire to father children and the partner of one of them became study and improved after corticosteroid administration. pregnant during the study and gave birth to a normal child.
Most patients showed some abnormalities in haematological Pregnancy was achieved in the fourth month of treatment or biochemical parameters, either before or during treatment, when the sperm concentration was 4.9 ϫ 10 6 /ml. which in general were not clinically relevant. Nine patients had a low basal red blood cell count, frequently accompanied Prognostic factors by a decrease in haemoglobin and/or haematocrit values, No significant differences were observed in the spermatogenic which generally improved during treatment. ANOVA showed response between the different diagnostic groups. The rate of a significant increase in mean red blood cell count (from complete responses in patients with isolated HH (63%) was 4.64 Ϯ 0.4 at pre-treatment to 5.0 Ϯ 0.4 ϫ 10 6 /µl at 6 months), quite similar to that observed in patients with multiple pituitary haemoglobin (from 13.8 Ϯ 1.1 to 15.0 Ϯ 1.3 g/dl) and haemdeficiencies (68%). Treatment efficacy was significantly related atocrit (from 40.5 Ϯ 3.2 to 44.3 Ϯ 3.4%) over the treatment to the onset of hypogonadism. Thus, in patients diagnosed of period. There was also a significant increase in creatinine, uric hypogonadism before puberty the response rate at the end of acid and alkaline phosphatase, whereas mean concentrations treatment was of 59.6%, whereas 100% of the eight patients of cholesterol, SGOT and SGPT were significantly decreased with hypogonadism of postpubertal onset showed an adequate by treatment. Physical examination, heart rate and blood response at 6 months (P Ͻ0.01). Likewise, maximum sperm pressure were always normal. At all visits the injection site concentration in patients with postpubertal onset hypogonadism was carefully examined with no local reactions observed in (37.9 Ϯ 14.5 ϫ 10 6 /ml) was significantly higher (P ϭ 0.04) any patient. than that observed in the rest of patients (22.3 Ϯ 8.5 ϫ 10 6 / ml, mean Ϯ SEM).
The spermatogenic response was not significantly related to Discussion previous treatments received by patients, although there was
To the best of our knowledge, the present study represents the a trend to a better response in patients treated with gonadotrolargest therapeutic trial in men with HH ever reported in the phins. Thus, nine out of 10 (90%) patients who were receiving literature. gonadotrophins before entering the study achieved spermatoRegarding the testicular steroidogenic response, testosterone genesis as compared to 78% of the rest of patients (P ϭ 0.3).
reached normal values in nearly all patients, which is consistent Likewise, the overall response rate in patients who had received with the data published by other authors (Finkel et al., 1985 ; FSH preparations was slightly higher than in the rest of patients Ley and Leonard, 1985; Saal et al., 1991; Mastrogiacomo (84.2 versus 77 .5%) but the difference was not significant. et al., 1991) . These figures are higher than those obtained by Neither the response rate nor maximum sperm concentration Okuyama et al. (1986) in patients with HH whose mean showed a significant association with basal or post-treatment testosterone concentrations were still below the normal range testicular size. Finally, the response rate in those patients who after 6 months of treatment with HCG and HMG. Likewise, were able to ejaculate at the beginning of the study (overall the response rate of the present study is higher than that response of 88.5%, 95% CI: 68.7-96.9%) was not significantly obtained by Kirk et al. (1994) in patients with HH treated with different from that observed in the subgroup of patients that slightly lower HCG doses. could not ejaculate at baseline (overall response of 73.5%,
The testicular volume experienced a dramatic, almost 3-fold 95% CI: 55.3-86.5%).
increase during treatment, although most patients did not reach normal values, which agrees with the results obtained by others Safety (Ley and Leonard, 1985; Liu et al., 1988; Saal et al., 1991; Kliesch et al., 1994) in patients treated with HMG ϩ HCG. Safety was assessed in a total of 63 patients who received at least one dose of FSH-HP. Only 11 patients (17.5%) reported
The spermatogenic response observed with the new preparation of highly purified FSH was comparable or even better some adverse event which, in most cases, was not serious and not considered as related to treatment. These included acute than that reported in patients treated with HMG ϩ HCG (Saal et al., 1991; Schopohl et al., 1991; Kirk et al., 1994) . hepatitis B, trauma, chest pain, dizziness, traumatic orchitis and biochemical abnormalities (increase in bilirubin, cholesterol or Although most patients did not reach a normal sperm concentration (ജ20 ϫ 10 6 /ml), normal values are currently uric acid). Six patients (9.5%) suffered from adverse events thought not to be absolutely necessary to achieve fertility (Van erythropoiesis (Wilson, 1991) . The increase in uric acid and creatinine could be related to anabolic effects of treatment. Zyl et al., 1975; Zukerman et al., 1977; Sheriff, 1983; Ley and Leonard, 1985; Sokol and Sparkes, 1987; Kliesch et al., Alkaline phosphatase increase was probably associated with body growth. 1994). This is particularly true in patients with HH who, after treatment with gonadotrophins, usually become fertile with Local tolerance to s.c. injections was excellent with no reactions at the injection site. sperm concentrations far below 20 ϫ 10 6 /ml (Burris et al., 1988) .
Treatment compliance was good with a very low rate of drop-outs, in spite of repeated injections administered for On the other hand, and taking into account the spermatogenic process, treatment duration in the present study was too short months. This confirms the great advantage of s.c. self-administration, allowed by the high purity of FSH. to normalize sperm concentration, since most of the enrolled patients were not seeking fertility at that time and the aim of
In conclusion, combined treatment with FSH-HP ϩ HCG is effective and safe to stimulate spermatogenesis, steroidogenesis the study was just to assess the ability of the treatment to induce spermatogenesis. A longer treatment period would and testicular growth in patients suffering from HH. certainly have been required to normalize sperm concentrations, as shown by Okuyama et al. (1986) who only achieved it inMastrogiacomo, I., Motta, R.G., Botteon, S. et al. (1991) Achievement of spermatogenesis and genital tract maturation in hypogonadotrophic not related to the study drug. In the present study only three hypogonadic subjects during long term treatment with gonadotropins or cases of gynaecomastia were observed; this incidence is lower LHRH. Andrologia, 23, [285] [286] [287] [288] [289] than that described by others (Schopohl et al., 1991; Kliesch McClure, R.D. (1987) Endocrine investigation and therapy. Urol. Clin. North Am., 14, 471-488. et al., 1994; Kirk et al., 1994) enon could be due to the stimulating effect of testosterone on
